Paltusotine

Brand names: Palsonify · Active ingredient: Paltusotine Hydrochloride

In short: PALSONIFY is indicated for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.

Forms & strengthsPALSONIFY Tablets: 20 mg: pink, biconvex oval tablets, debossed with “PAL” on one side and “20” on the other side; contains 20 mg paltusotine free base. …
LabelCrinetics Pharmaceuticals, Inc.
Label updatedOct 03, 2025

What is Paltusotine used for?

PALSONIFY is indicated for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.

Paltusotine dosage

Take PALSONIFY orally once daily with water on an empty stomach, at least 6 hours after a meal (e.g., after overnight fasting) and at least 1 hour before the next meal .

The recommended initial dosage of PALSONIFY is 40 mg once daily.

During initiation period, PALSONIFY may be temporarily reduced to 20 mg once daily if needed, based on tolerability . Once adverse reactions have resolved, resume PALSONIFY 40 mg once daily.

After 2 to 4 weeks on PALSONIFY 40 mg once daily, based on IGF-1 levels, titrate to a PALSONIFY dosage of 60 mg once daily.

Concomitant Use with Strong CYP3A4 Inducers

Patients taking strong CYP3A4 inducers may require an increased dosage of PALSONIFY. Do not exceed three-fold the PALSONIFY dosage prior to concomitant use or 120 mg daily, whichever is less .

Concomitant Use with Moderate CYP3A4 Inducers

Patients taking moderate CYP3A4 inducers may require an increased dosage of PALSONIFY. Do not exceed two-fold the PALSONIFY dosage prior to concomitant use or 120 mg daily, whichever is less .

Concomitant Use with Proton Pump Inhibitors

Patients taking proton pump inhibitors may require an increased dosage of PALSONIFY. Avoid concomitant use of proton pump inhibitors in patients who are already on PALSONIFY 60 mg .

How to take Paltusotine — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Cholelithiasis and its Complications

Advise patients to contact their healthcare provider if they experience signs or symptoms of gallstones (cholelithiasis) or complications of cholelithiasis (e.g., cholecystitis, cholangitis, and pancreatitis) .

Hyperglycemia and Hypoglycemia

Advise patients to contact their healthcare provider if they have problems with blood sugar levels, either hyperglycemia or hypoglycemia .

Cardiovascular Abnormalities

Advise patients to contact their healthcare provider if they notice irregular heartbeat .

Thyroid Function Abnormalities

Advise patients that their thyroid function may be assessed periodically .

Steatorrhea and Malabsorption of Dietary Fats

Advise patients to contact their healthcare provider if they experience new or worsening symptoms of steatorrhea, loose stools, abdominal bloating, weight loss .

Vitamin B

12

Deficiency

Advise patients that Vitamin B12 levels may be monitored during treatment .

PALSONIFY is a trademark of Crinetics Pharmaceuticals, Inc. ©2025 Crinetics Pharmaceuticals, Inc. All rights reserved. …

Warnings & precautions

Do not take this medicine if: None.

PALSONIFY may inhibit gallbladder contractility and decrease bile secretion, which may lead to gallbladder stones or sludge. Cholelithiasis was reported in participants treated with PALSONIFY in clinical trials. Complications of cholelithiasis, such as acute cholecystitis and pancreatitis, have also been reported with the use of PALSONIFY . Monitor patients periodically. If complications of cholelithiasis occur, discontinue PALSONIFY and treat appropriately.

PALSONIFY may alter the balance between the counter-regulatory hormones, insulin, glucagon, and growth hormone, which may result in hypoglycemia, hyperglycemia, or diabetes mellitus. Hyperglycemia was reported in participants treated with PALSONIFY in clinical trials . Monitor blood glucose levels when PALSONIFY treatment is initiated or when the dose is altered. Adjust antidiabetic treatment accordingly.

Cardiac conduction abnormalities and other ECG changes such as PR interval prolongation have occurred during treatment with PALSONIFY. Bradycardia, sinus arrest, and atrioventricular block were reported in participants treated with PALSONIFY in clinical trials . These ECG changes may occur in patients with acromegaly. Dosage adjustments of concomitantly used drugs that have bradycardia effects (e.g., beta-blockers) may be necessary.

Somatostatin analogs may suppress the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. Periodic assessment of thyroid function (TSH, total, and/or free T4) is recommended during treatment with PALSONIFY.

New onset steatorrhea, stool discoloration and loose stools have been reported in patients receiving somatostatin analogs. …

Paltusotine side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:

Cholelithiasis and Complications of Cholelithiasis

Hyperglycemia and Hypoglycemia

Cardiovascular Abnormalities

Thyroid Function Abnormalities

Steatorrhea and Malabsorption of Dietary Fats

Changes in Vitamin B12 Levels

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of PALSONIFY was evaluated in adults with acromegaly in two randomized, double-blind, placebo-controlled Phase 3 studies. Study 1 was a 24-week, randomized, placebo-controlled study in 111 adults who were naive or previously treated on a somatostatin analog and biochemically uncontrolled at randomization. Participants in Study 1 had a mean age of 47 years (range: 18 to 80 years) and were randomized to PALSONIFY (n=54) or placebo (n=57) . Study 2 was a 36-week, randomized, placebo-controlled study in 58 adults who were biochemically controlled on injectable depot formulations of octreotide or lanreotide. Participants in Study 2 had a mean age of 55 years (range: 29 to 84 years) and were randomized to PALSONIFY (n=30) or placebo (n=28) . …

Drug interactions

Strong CYP3A4 Inducers

Intervention | Concomitant use of PALSONIFY with strong CYP3A4 inducers may require an increased dosage of PALSONIFY, not to exceed three-fold the dose prior to concomitant use or 120 mg daily, whichever is less.

Clinical Impact | Concomitant use of PALSONIFY with strong CYP3A4 inducers reduced paltusotine exposure and may affect therapeutic response .

Moderate CYP3A4 Inducers

Intervention | Concomitant use of PALSONIFY with moderate CYP3A4 inducers may require an increased dosage of PALSONIFY, not to exceed two-fold the dose prior to concomitant use or 120 mg daily, whichever is less.

Clinical Impact | Concomitant use of PALSONIFY with moderate CYP3A4 inducers resulted in a decrease in paltusotine exposure .

Proton Pump Inhibitors

Intervention | Concomitant use of PALSONIFY with PPIs may require an increased dosage of PALSONIFY. Patients who are already on PALSONIFY 60 mg should avoid concomitant use with proton pump inhibitors.

Clinical Impact | Concomitant use of PALSONIFY with proton pump inhibitors demonstrated a dose-dependent decrease in paltusotine exposure .

Cyclosporine

Intervention | Adjustment of cyclosporine dose to maintain therapeutic levels may be necessary. Follow recommended therapeutic drug monitoring for cyclosporine. …

About this medicine

PALSONIFY tablets contain paltusotine hydrochloride, a somatostatin receptor agonist. Paltusotine is known chemically as 3-[4-(4-Amino-1-piperidinyl)-3-(3,5-difluorophenyl)-6-quinolinyl]-2-hydroxybenzonitrile hydrochloride. The molecular weight of paltusotine hydrochloride is 492.95 g/mol (C27H22F2N4O·HCl).

PALSONIFY tablets for oral administration contain 20 mg of paltusotine (equivalent to 21.6 mg of paltusotine hydrochloride) or 30 mg of paltusotine (equivalent to 32.4 mg of paltusotine hydrochloride). Each tablet contains the following inactive ingredients: colloidal silicon dioxide, copovidone, crospovidone, magnesium stearate, mannitol, and microcrystalline cellulose. Additionally, the 20 mg tablets contain Opadry pink coating (hypromellose, iron oxide red, iron oxide yellow, titanium dioxide, and triacetin) and the 30 mg tablets contain Opadry yellow coating (hypromellose, iron oxide yellow, titanium dioxide, and triacetin).

How it works: Similar to the natural hormone somatostatin, paltusotine suppresses growth hormone (GH) and insulin-like growth factor-1 (IGF-1) secretion. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 8a6d2ce0-a621-4ee7-983c-977cd948ff4d. Read the full official label on DailyMed.